Allergan   3Q Revenues: $3.6 billion (+4%) 3Q Earnings: $15.2 billion (earnings were $5.2 billion 3Q15)* YTD Revenues: $10.7 billion (+18%) YTD Earnings: $15.0 billion (earnings were $4.5 billion YTD15)* Comments: Growth in the quarter was driven key brands and new product launches, offset by the loss of ASACOL HD exclusivity, lower revenues for NAMENDA XRand IR, a decline in non-promoted Established Brands revenues and unfavorable foreign exchange. ASACOL sales were down to $72.2 ...